Gout and pseudogout are the 2 most common crystal-induced arthropathies. Gout is caused by monosodium urate monohydrate crystals; pseudogout is caused by calcium pyrophosphate crystals. There is evidence that gout and heart disease are mechanistically linked by inflammation and patients with gout are at elevated risk for cardiovascular (CV) disease.
The case–control study, which involved more than 60,000 patients with a recent gout diagnosis, some who went on to have MI or stroke, looked at rates of such events at different time intervals after gout flares. Those who experienced such events showed a more than 90% increased likelihood of a gout flare-up in the preceding 60 days, a greater than 50% chance of a flare between 60 and 120 days before the event, but no increased likelihood prior to 120 days before the event.
They can immobilize patients, possibly raising their risk for thrombotic events, for example. They can be exceptionally painful, which causes stress and can lead to frequent or chronic use of glucocorticoids or nonsteroidal anti-inflammatory drugs (NSAIDs), all of which can exacerbate high blood pressure and possibly worsen CV risk.
An alternative to universal augmentation of cardiovascular risk prevention with therapies among patients with gout flares would be to further stratify risk by defining a group at highest near-term risk.
Such interventions could potentially be guided by markers of CV risk such as, for example, levels of high-sensitivity C-reactive protein (hs-CRP) or lipoprotein(a), or plaque burden on coronary-artery calcium scans.
Stem Cell therapy can help to improve the symptoms of the gout disease by regulating the inflammatory process and decreasing the levels of uric acid, as a result of better mobility of the affected limb and improve your life quality. Moreover as we see in this study, MSCs could diminish the high risk of Cardiovascular events linked with gout.
Edoardo Cipolletta, MD; Laila J. Tata, PhD Georgina Nakafero, PhD; et al. (August 2, 2022). Association Between Gout Flare and Subsequent Cardiovascular Events Among Patients With Gout. JAMA. Retrieved from : https://jamanetwork.com/journals/jama/article-abstract/2794763